|Bid||10.65 x 0|
|Ask||10.72 x 0|
|Day's Range||10.56 - 11.07|
|52 Week Range||1.90 - 15.20|
|PE Ratio (TTM)||595.56|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.99|
Last week, the state of Pennsylvania saw some of its first few medical marijuana (MJX) dispensaries opening doors to patients suffering from one of 17 “serious medical conditions.” This event came on the heels of more and more jurisdictions around the world recognizing marijuana for medical purposes. Medical marijuana was legalized in Pennsylvania in 2016. Marijuana is classified as a Schedule 1 drug under the act.
Canopy Growth Corp. (TSX:WEED) reported strong revenue growth in its third quarter, but growth should be even higher following legalization.
Marijuana giant Canopy Growth Corp. (TSX:WEED) reported impressive revenue growth on Wednesday, but more work needs be done to justify high stock valuation metrics.
In the earlier parts of this series, we discussed how Canopy Growth (WEED) fared in terms of selling prices, sales volumes, and cost of production. While the company’s cost of production fell 1.9% year-over-year, its selling price rose 13% over the same period. During fiscal 3Q18, Canopy Growth reported a non-GAAP (generally accepted accounting principles) gross margin of 58% of sales, which included the cash operating costs associated with the company’s subsidiaries that aren’t currently cultivating or selling cannabis.
In the earlier part of this series, we discussed Canopy Growth’s sales drivers and how the company’s selling prices increased year-over-year. At the same time, the company also managed to lower its cost of production. In its press release, Canopy Growth reported that its per gram weighted average cost before shipping and fulfillment fell 39% to 1.03 Canadian dollars from 1.7 Canadian dollars in 3Q17.
Canopy Growth Corp. (TSX:WEED) leadership is projecting that Canada’s cannabis market could be worth up to $10 billion, and rising sales in U.S. states appear to back up that optimism.
There has been a great deal of enthusiasm recently among investors (MJX) when it comes to cannabis stocks. Of course, the biggest catalyst for sales growth has come from recreational use in Canada. In addition, an increase in medical and recreational cannabis use around the world may also drive sales growth for these companies.
EDMONTON, Alberta, Feb. 14, 2018-- Aurora Cannabis Inc. and Liquor Stores N.A. Ltd. announced today the closing of the previously announced strategic investment by Aurora in Liquor Stores by way of a non-brokered ...
The recently announced $104 million investment by Aurora Cannabis Inc. (TSX:ACB) in Liquor Stores N.A. Ltd. (TSX:LIQ) is a good one. Here's why.
Will there be so much love for marijuana giant Canopy Growth Corp.’s (TSX:WEED) stock after it reports its quarterly results on Valentine’s Day?
Shopify Inc. (TSX:SHOP)(NYSE:SHOP) rallied off news that the LCBO is using its e-commerce platform to sell marijuana, but where will the stock go from here?
Although Canopy Growth Corp. (TSX:WEED) has seen its share price tumble lately, it's only a matter of time before the stock goes back on the ascent.
Aurora Cannabis Inc. (TSX:ACB) may be delivering desired marijuana business growth, but the latest quarterly earnings results show a mixed bag of fortunes.
Instead of focusing all of your attention on the big cannabis players, look at smaller companies such as Cronos Group Inc. (TSXV:MJN) or Emerald Health Therapeutics, Inc. (TSXV:EMH) in this acquisition-heavy environment.
Canopy Growth Corp. (TSX:WEED) is down up to 38% since January in a reversal of investor sentiment that may have only just begun.
Just when you thought pot stocks such as Aurora Cannabis Inc. (TSX:ACB) were the riskiest securities, this insidious new instrument shows its ugly head.
Canopy Growth Corp (TSX:WEED) and other pot stocks expecting cannabis to be legalized this summer could be in for a big disappointment.